Details of the Drug

General Information of Drug (ID: DM7IW9J)

Drug Name
Ramelteon
Synonyms
Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2]
Circadian rhythm sleep disorder 7A60-7A65 Terminated [1], [2]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.339
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The absorption of drug is at least 84% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 13.1 mL/min/kg [5]
Elimination
0.1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2.6 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4407 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.2% [5]
Vd
The volume of distribution (Vd) of drug is 73.6 L [7]
Chemical Identifiers
Formula
C16H21NO2
IUPAC Name
N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide
Canonical SMILES
CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3
InChI
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
InChIKey
YLXDSYKOBKBWJQ-LBPRGKRZSA-N
Cross-matching ID
PubChem CID
208902
ChEBI ID
CHEBI:109549
CAS Number
196597-26-9
DrugBank ID
DB00980
TTD ID
D0U0KW
INTEDE ID
DR1391
ACDINA ID
D00581

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melatonin receptor type 1A (MTNR1A) TT0WAIE MTR1A_HUMAN Modulator [8], [9]
Melatonin receptor type 1B (MTNR1B) TT32JK8 MTR1B_HUMAN Modulator [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ramelteon (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Ramelteon caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [57]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Ramelteon caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [57]
Arn-509 DMT81LZ Moderate Increased metabolism of Ramelteon caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [57]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Ramelteon and Oliceridine. Acute pain [MG31] [58]
Posaconazole DMUL5EW Moderate Decreased metabolism of Ramelteon caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [57]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Ramelteon caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [57]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Ramelteon caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Norfloxacin DMIZ6W2 Moderate Decreased metabolism of Ramelteon caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Ramelteon caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Ramelteon caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [57]
Tucatinib DMBESUA Moderate Decreased metabolism of Ramelteon caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Alpelisib DMEXMYK Moderate Increased metabolism of Ramelteon caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Niclosamide DMJAGXQ Moderate Decreased metabolism of Ramelteon caused by Niclosamide mediated inhibition of CYP450 enzyme. Cestodes infection [1F70-1F76] [57]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Ramelteon and Dihydrocodeine. Chronic pain [MG30] [60]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Ramelteon caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [57]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Ramelteon caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [61]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ramelteon caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [62]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Ramelteon caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [57]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Ramelteon and Esketamine. Depression [6A70-6A7Z] [63]
Cenobamate DMGOVHA Moderate Increased metabolism of Ramelteon caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [57]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Ramelteon caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [57]
Phenobarbital DMXZOCG Moderate Increased metabolism of Ramelteon caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [57]
Tazemetostat DMWP1BH Moderate Increased metabolism of Ramelteon caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [57]
Itraconazole DMCR1MV Moderate Decreased metabolism of Ramelteon caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [57]
Miconazole DMPMYE8 Moderate Decreased metabolism of Ramelteon caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [57]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Ramelteon caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [57]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Ramelteon caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [57]
Boceprevir DMBSHMF Moderate Decreased metabolism of Ramelteon caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Telaprevir DMMRV29 Moderate Decreased metabolism of Ramelteon caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Rifampin DMA8J1G Moderate Increased metabolism of Ramelteon caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [64]
Rifapentine DMCHV4I Moderate Increased metabolism of Ramelteon caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [57]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Ramelteon caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Ramelteon caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Saquinavir DMG814N Moderate Decreased metabolism of Ramelteon caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Etravirine DMGV8QU Moderate Increased metabolism of Ramelteon caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Darunavir DMN3GCH Moderate Decreased metabolism of Ramelteon caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Atazanavir DMSYRBX Moderate Decreased metabolism of Ramelteon caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Ramelteon caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [57]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Ramelteon caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [63]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Ramelteon caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [57]
Givosiran DM5PFIJ Moderate Decreased metabolism of Ramelteon caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [57]
Ceritinib DMB920Z Moderate Decreased metabolism of Ramelteon caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [57]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ramelteon caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [57]
Osimertinib DMRJLAT Moderate Increased metabolism of Ramelteon caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [57]
Capmatinib DMYCXKL Moderate Decreased metabolism of Ramelteon caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [57]
Selpercatinib DMZR15V Moderate Decreased metabolism of Ramelteon caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
Primaquine DMWQ16I Moderate Decreased metabolism of Ramelteon caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [57]
Idelalisib DM602WT Moderate Decreased metabolism of Ramelteon caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [57]
IPI-145 DMWA24P Moderate Decreased metabolism of Ramelteon caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [67]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Ramelteon caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [57]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ramelteon caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [57]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Ramelteon and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [68]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Ramelteon and Lasmiditan. Migraine [8A80] [69]
Exjade DMHPRWG Moderate Decreased metabolism of Ramelteon caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [57]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Ramelteon and Flibanserin. Mood disorder [6A60-6E23] [70]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Ramelteon and Thalidomide. Multiple myeloma [2A83] [71]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Ramelteon caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [72]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Ramelteon and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Ramelteon caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [57]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Ramelteon and Oxymorphone. Pain [MG30-MG3Z] [58]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Ramelteon and Dezocine. Pain [MG30-MG3Z] [58]
Abametapir DM2RX0I Moderate Decreased metabolism of Ramelteon caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [73]
Lefamulin DME6G97 Moderate Decreased metabolism of Ramelteon caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [74]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Ramelteon caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [57]
Enzalutamide DMGL19D Moderate Increased metabolism of Ramelteon caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [57]
Dexamethasone DMMWZET Moderate Increased metabolism of Ramelteon caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [57]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ramelteon caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [64]
Larotrectinib DM26CQR Moderate Decreased metabolism of Ramelteon caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [63]
Armodafinil DMGB035 Moderate Increased metabolism of Ramelteon caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [57]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ramelteon caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [75]
Elagolix DMB2C0E Moderate Increased metabolism of Ramelteon caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [57]
Propafenone DMPIBJK Moderate Decreased metabolism of Ramelteon caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [57]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Ramelteon caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [57]
⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ramelteon 8 mg tablet 8 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1356).
2 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
9 Ramelteon: a melatonin receptor agonist for the treatment of insomnia. J Postgrad Med. 2008 Jan-Mar;54(1):45-8.
10 Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
11 Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
31 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
32 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
33 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
34 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
36 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
37 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
38 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
39 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
40 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
41 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
42 Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
43 Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
44 Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
45 Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
46 Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
47 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
48 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
50 Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
51 Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
52 Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
53 Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
54 US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
55 Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.
56 US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality.
57 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
58 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
59 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
60 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
61 Cerner Multum, Inc. "Canadian Product Information.".
62 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
63 Cerner Multum, Inc. "Australian Product Information.".
64 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
65 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
66 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
67 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
68 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
69 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
70 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
71 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
72 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
73 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
74 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
75 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.